SUMMIT, N.J., Dec. 3, 2025 /PRNewswire/ — Vascarta Inc., is pleased to share results from a new study led by researchers at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER), […]
Tag: Vascarta Inc.
Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
SUMMIT, N.J., Nov. 3, 2025 /PRNewswire/ — New findings demonstrating a reversal in acute vaso-occlusive pain in sickle cell disease by a novel transdermal curcumin gel formulation to be presented* at the 67th Annual American Society […]
Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
SUMMIT, N.J., Nov. 3, 2025 /PRNewswire/ — New findings demonstrating a reversal in acute vaso-occlusive pain in sickle cell disease by a novel transdermal curcumin gel formulation to be presented* at the 67th Annual American Society […]
Using the original title “Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis”, create a new title that is SEO-optimized, engaging, and fewer than 15 words. Incorporate the main focus keyword naturally and ensure the title accurately reflects the essence of the original. Do not include any part of this prompt or instructions in your response. Only provide the rewritten title. Avoid using the phrases: “rewrite,” “rewrite the title,” or “rewrite the following content.”
Transform the following content into a 1,500-word article: SUMMIT, N.J., Nov. 3, 2025 /PRNewswire/ — New findings demonstrating a reversal in acute vaso-occlusive pain in sickle cell disease by a novel transdermal curcumin gel formulation […]
Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis
SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ — Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the […]
